Pharmacotherapeutic group: Androgens. ATC code G03B A03 Treatment of hypogonadal men with Susobolic 250 results in a clinically significant rise of plasma concentrations of testosterone, dihydrotestosterone, estradiol and androstenedione, as well as decrease of SHBG (Sex hormone binding globulin). Luteinizing  hormone (LH) and follicle-stimulating hormone (FSH) are restored to the normal range. In hypogonadal men, treatment with Cooper Susobolic 250 results in an improvement of  testosterone deficiency symptoms. Moreover, treatment increases bone mineral density and lean body mass, and decreases body fat mass. Treatment also improves  sexual function, including libido and erectile function. Treatment decreases serum LDL-C, HDL-C and triglycerides and increases haemoglobin and  haematocrit, which may lead to polycythaemia. No clinically relevant changes in liver enzymes and PSA have been reported. Testosterone also produces systemic effects,  such as increasing the retention of sodium, potassium and chloride leading to an increase in water retention. Treatment may result in an increase in prostate size, and  worsening of lower urinary tract symptoms, but no adverse effects on prostate symptoms have been observed. In hypogonadal diabeteic patients, improvement of insulin  sensitivity and/or reduction in blood glucose have been reported with the use of androgens. In boys with constitutional delay of growth and puberty, treatment with  Susobolic 250 accelerates growth and induces development of secondary sex characteristics. In female-to-male transsexuals, treatment with Susobolic 250 induces  masculinisation. Pharmacokinetics Susobolic 250 contains four esters of testosterone with different durations of action. The esters are hydrolysed into the natural hormone  testosterone as soon as they enter the general circulation.

Absorption:
A single dose of Susobolic 250 leads to an increase of total plasma testosterone with peak levels of approximately 70nmol/l (Cmax), which are reached approximately 24-48 h (tmax) after administration. Plasma testosterone levels return to the lower limit of the normal range in males in approximately 21 days. In female-to-male transsexuals, a single dose of Susobolic 250 repeated every two weeks resulted in mean trough testosterone levels towards the upper end of the normal male range at 2, 4 and 12 months.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Due to the nature of Susobolic 250 side effects cannot be quickly reversed by discontinuing medication. Injectables in general, may cause a local reaction at the injection  site.

synonyms and related terms.